Orgenesis (ORGS) Stock Price, News & Analysis

Company Overview

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Key Stats

• Today's Range: $2.01 to $2.01
• 50-Day Range: $1.77 to $3.49
• 52-Week Range: $0.87 to $10.80
• Volume: 2 shs
• Average Volume: 9,768 shs
• Market Capitalization: $9.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ORGS Stock Analysis - Frequently Asked Questions

How have ORGS shares performed this year?

Orgenesis' stock was trading at $1.89 at the beginning of 2025. Since then, ORGS stock has increased by 6.3% and is now trading at $2.01.
View the best growth stocks for 2025 here.

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NASDAQ:ORGS) issued its quarterly earnings data on Friday, August, 11th. The company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of $0.60 by $2.10. The business had revenue of $6.98 million for the quarter.

When did Orgenesis' stock split?

Shares of Orgenesis reverse split before market open on Wednesday, September 25th 2024. The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Does Orgenesis have any subsidiaries?

Orgenesis subsidiaries include Koligo Therapeutics, and Tamir Biotechnology Inc.

How do I buy shares of Orgenesis?

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Orgenesis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 5/22/2025
• Next Earnings (Estimated): 5/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORGS
• CIK: 1460602
• Web: www.orgenesis.com
• Phone: (480) 659-6404
• Fax: N/A
• Employees: 150
• Year Founded: 2008

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-55,360,000.00
• Net Margins: -3,827.81%
• Pretax Margin: -3,931.93%
• Return on Equity: N/A
• Return on Assets: -130.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $662,000.00
• Price / Sales: 14.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.58) per share
• Price / Book: -0.31

Miscellaneous

• Outstanding Shares: 4,799,000
• Free Float: 4,527,000
• Market Cap: $9.65 million
• Optionable: No Data
• Beta: 0.72